Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium

• Egile Nagusiak: Lander Willem (Egilea), Adriaan Blommaert (Egilea), Germaine Hanquet (Egilea), Nancy Thiry (Egilea), Joke Bilcke (Egilea), Heidi Theeten (Egilea), Jan Verhaegen (Egilea), Herman Goossens (Egilea), Philippe Beutels (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2018-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Streptococcus pneumoniae causes a high disease burden including pneumonia, meningitis and septicemia. Both a polysaccharide vaccine targeting 23 serotypes (PPV23) and a 13-valent conjugate vaccine (PCV13) are indicated for persons aged over 50 years. We developed and parameterized a static multi-coh...